Skip to main content

Oil-Dri Announces Issuance of U.S. Patent for Mineral-Based Technology for Use in Antibiotic-Free Animal Protein Production

CHICAGO, Aug. 24, 2020 (GLOBE NEWSWIRE) — Oil-Dri Corporation of America (NYSE: ODC), a leading manufacturer of sorbent minerals, parent company to Amlan International, today announced that the United States Patent and Trademark Office has issued U.S. Patent 10,568,903 entitled “Clay Product and Uses Thereof.” The patent covers two existing commercial products, Varium® for poultry and NeoPrime™ for swine, that are helping global animal protein producers thrive in an era of antibiotic-free production. 
This patent provides a methodology for using a natural, mineral-based formula to mitigate the effects of exposure to pathogenic bacteria and the disease-causing toxins they produce, which damage gut health and function. Advancements in natural feed additives are helping to transform animal protein production by providing proven and reliable alternatives to in-feed antibiotics used to promote growth and productivity.  “The United States is the second country to issue a patent for this mineral-based technology and it validates the important role that minerals play in disrupting the cycle of intestinal disease,” said Daniel S. Jaffee, President and CEO of Oil-Dri Corporation of America. “When using Varium, for example, poultry integrators have eliminated the use of in-feed antibiotics to promote growth while maintaining production efficiencies and profitability. Our customers report they are growing healthier birds that are less stressed and have increased the marketability of their products through improved skin, liver and feet quality.”“The market opportunity for natural alternatives to antibiotics is large and growing,” says Flemming L. Mahs, President of Amlan International, a Nevada corporation. “Market data indicates that within medicinal feed additives, anti-infectives are a $2.4 billion global market and usage has been declining as a result of changing consumer sentiment towards the use of antibiotics and regulatory restrictions limiting the use of antibiotics in animal protein production. Intestinal disease costs the global livestock industry more than $6 billion annually in economic loss and costs are rising as sub-therapeutic antibiotic use declines.”Mineral-Based TechnologyUnlike antibiotics, which are designed to kill bacteria, the patented technology includes a synergistic formula of three ingredients with distinct modes of action: (1) a surface-activated mineral that facilitates chemical binding of pathogenic intestinal bacteria and the disease-causing toxins they produce; (2)  an immunomodulator that stimulates an animal’s innate immune system to naturally defend against disease; and (3) an energy source for the replenishment of intestinal epithelial cells that is essential for healthy gut function. Upon inclusion of this patented technology in animal feed, current producers have effectively eliminated the use of antibiotics to promote growth and have experienced equivalent or better outcomes.Amlan InternationalOil-Dri Corporation of America (NYSE: ODC), a Delaware corporation doing business as “Amlan International,” is a global leader in proven solutions that improve the intestinal health and productivity of livestock. Amlan has grown its product offering across the intestinal health and AGP-alternative market, driven largely by the research conducted at its laboratory campus in Vernon Hills, Illinois.Amlan International sells animal health products outside of the United States. Product associated claims do not constitute medical claims and may differ based on government requirements. Product availability may vary by country.Reagan Culbertson
Media Contact
press@amlan.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.